{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:22:43Z","timestamp":1788459763111,"version":"build-2803163510"},"reference-count":0,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"6815","content-domain":{"domain":["www.science.org"],"crossmark-restriction":true},"short-container-title":["Science"],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:p>It is difficult to overstate how much glucagon-like peptide-1 (GLP-1) pharmacotherapies have inundated the public discourse on obesity. An avalanche of scientific papers, news articles, and social media posts debate the efficacy, affordability, and appropriateness of GLP-1 receptor agonists not just for obesity but also skin disease, erectile dysfunction, pregnancy, and addiction. Attempting to cut through the noise, the World Health Organization (WHO) recently published the first-ever global guidelines recommending GLP-1s for the treatment of obesity, while committing to develop a global framework ensuring \u201cfair access\u201d to these medicines for the 1 billion people affected worldwide. Going deeper, the guidelines also advocate for \u201crobust populationlevel policies\u201d to address the root causes of obesity in unhealthy food environments. However, to complicate these efforts, WHO\u2019s recommendations unfold at a time rife with competitive pressures among pharmaceutical companies, food companies vying for the GLP-1 market segment, and wellness companies promoting supplements and telemedicine programs for what is being billed as a GLP-1 lifestyle. This commercial milieu is ripe for unintended consequences that conspire against fair access to these medicines.<\/jats:p>","DOI":"10.1126\/science.ael8715","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:00:43Z","timestamp":1788458443000},"page":"953-953","update-policy":"https:\/\/doi.org\/10.34133\/aaas_crossmark","source":"Crossref","is-referenced-by-count":0,"title":["(Un)intended consequences of mass-prescribing GLP-1s"],"prefix":"10.1126","volume":"393","author":[{"given":"Luc L.","family":"Hagenaars","sequence":"first","affiliation":[{"name":"Luc L. Hagenaars is an assistant professor in the Department of Public and Occupational Health, Amsterdam UMC Location, University of Amsterdam, Amsterdam, Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Laura A. Schmidt is a professor at the Philip R. Lee Institute for Health Policy Studies, School of Medicine, University of California San Francisco, San Francisco, CA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","container-title":["Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.science.org\/doi\/pdf\/10.1126\/science.ael8715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:00:49Z","timestamp":1788458449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.science.org\/doi\/10.1126\/science.ael8715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":0,"journal-issue":{"issue":"6815","published-print":{"date-parts":[[2026,9,3]]}},"alternative-id":["10.1126\/science.ael8715"],"URL":"https:\/\/doi.org\/10.1126\/science.ael8715","relation":{},"ISSN":["0036-8075","1095-9203"],"issn-type":[{"value":"0036-8075","type":"print"},{"value":"1095-9203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"2026-09-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}